New CAR-T therapy targets Tough-to-Treat blood cancers
Disease control
Recruiting now
This early-stage trial is testing a new CAR-T cell therapy called ARD103 for patients with acute myeloid leukemia or myelodysplastic syndrome that has returned or hasn't responded to previous treatments. The study aims to find the safest and most effective dose while checking if …
Phase: PHASE1, PHASE2 • Sponsor: ARCE Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC